+Items related to biologics will be added to the top of the list as they are posted on the site.
04/29/2026 April 28, 2026 Approval Letter - AREPANRIX 04/29/2026 April 28, 2026 Approval Letter - GAMUNEX-C 04/27/2026 Vaccines and Related Biological Products Advisory Committee Meeting Announcement Date: May 28, 202604/23/2026 April 23, 2026 Approval Letter - OTARMENI 04/23/2026 April 22, 2026 Approval Letter - VIMKUNYA 04/23/2026 Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers; Guidance for Industry 04/21/2026 April 20, 2026 Approval Letter - ERVEBO 04/21/2026 March 31, 2026 Approval Letter - Elecsys HIV Duo 04/15/2026 Pediatric Tracking Requirements Under FDAAA 04/15/2026 March 26, 2026 Summary Basis for Regulatory Action - KRESLADI 04/14/2026 Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry 04/10/2026 April 10, 2026 Approval Letter - THROMBIN-JMI LIQUID 04/10/2026 SOPP 8001.4: Review of Proprietary Names for CBER Regulated Products 04/09/2026 SOPP 8216: Fast Track Development Programs - Designation and Management 04/09/2026 SOPP 8212: Breakthrough Therapy Products - Designation and Management 04/07/2026 April 1, 2026 Approval Letter - Profilnine SD - Factor IX Complex 04/03/2026 BK251289- Plasmacell-C Disposable Set 04/02/2026 April 1, 2026 Approval Letter - TECARTUS 04/02/2026 SOPP 8404.1: Procedures for Filing an Application When the Applicant Protests a Refusal to File Action (File Over Protest) 04/02/2026 Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle; Guidance for Industry and Food and Drug Administration Staff 03/30/2026 March 27, 2026 Approval Letter - PRIORIX 03/27/2026 BK251300- Procleix Plasmodium Quality Control 03/27/2026 March 26, 2026 Approval Letter - KRESLADI
Content current as of:
04/29/2026